Lisata Therapeutics, Inc. (LSTA) income statement
LSTANasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 6/30
$0.98−0.06 (-5.76%)
Close on Nov 18, 2026Market cap $8.83MP/E –Yield –
Lisata Therapeutics, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- –
- Operating margin
- -16427.0%
- Net margin
- -14621.0%
- Return on equity, FY2025
- -74.7%
Financial strength
- Current ratio
- 3.69
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 349.6%
Valuation
- P/E ratio
- –
- Price to sales
- 88.32
- Price to book
- 1.07
- Dividend yield
- –
See a number that looks wrong?